ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

Health Association Oppose U.S. Trade Policy On Tobacco Exports; Recommend Restrictions

August 25, 1989

NCI-Approved Clinical Trials Listed For January

January 28, 2005

Foundation Issues Call For Tobacco Policy Research Proposals

November 27, 1992

NCI sponsors Year-Round Shannon Awards Program

April 4, 1996

In Brief: Subcommittee Adds $16-18 Million o NVI Budget; Upton Might Leave If Bill Fails

May 25, 1979

Hawkins Persists In Attacks On NCI Despite Testimony Refuting Charges

November 13, 1981